Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing observational study of Unituxin in Japanese patients with neuroblastoma after high-dose chemotherapy
jRCT2031210508Recruiting
- Sponsor
- Ohara Pharmaceutical Co., Ltd.
- Start
- Dec 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of dinutuximab in neuroblastoma, sponsored by Ohara Pharmaceutical Co., Ltd. Primary endpoints: Safety profile and adverse event incidence, Prognosis survey and 3 more. Started Dec 2021; status: recruiting.
02
Drugs
dinutuximab
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on jRCT2031210508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210508.